Dengue fever secondary prevention: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2. | Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype [[DENV-1]] contracts serotype [[DENV-2]] or [[DENV-3]], or if someone previously exposed to [[DENV-3]] acquires [[DENV-2]]. | ||
==References== | ==References== | ||
Revision as of 16:38, 15 June 2014
|
Dengue Fever Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dengue fever secondary prevention On the Web |
|
American Roentgen Ray Society Images of Dengue fever secondary prevention |
|
Risk calculators and risk factors for Dengue fever secondary prevention |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Although there is no commercially available vaccine for Dengue fever, it is notable that infection with one serotype is thought to produce lifelong immunity to that type, but only short term protection against the other three. Unfortunately, the risk of severe disease from secondary infection actually increases if someone previously exposed to serotype DENV-1 contracts serotype DENV-2 or DENV-3, or if someone previously exposed to DENV-3 acquires DENV-2.